When the cure kills

Deaths of three Aarhus cancer patients may have been caused by an overdose of chemotherapy

Some 28 cancer patients being treated at Aarhus University hospital were given an overdose of the chemotherapy drug cabazitaxel. The deaths of three patients may be directly related to the overdoses, which were 16-21 percent higher than the recommended amount of the drug. The overdoses, which were given mostly to prostate cancer victims, resulted in more violent side effects than usual.

“This is a critical and totally unacceptable situation,” Ole Thomsen, the head of health Region Midtjylland, told DR Nyheder.

The hospital sent letters explaining the mistake yesterday to the surviving patients and relatives of those who have died.

READ MORE: Thousands dying from hospital errors each year

Patients were offered a consultation to discuss the mistake and treatment options. They were also informed that they can apply for compensation from the Patient Insurance Association.





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.